A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.
Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...
Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.
An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has appointed Australian contract research organisation Beyond ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
Researchers at New York University Abu Dhabi (NYUAD) have developed Spheromatrix, a simple and low-cost technology that enables tumor models to be grown, frozen, and stored for future use in cancer ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
Ionetix, a mid-Michigan cancer treatment company, receives workforce development funding to train employees in advanced drug development technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback